Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Analyst Recommendations on ELI LILLY AND COMPANY
06/15ELI LILLY ANDá : JPMorgan Adjusts Price Target on Eli Lilly to $260 From $240, M..
MT
06/14ELI LILLY ANDá : Bernstein Adjusts Price Target on Eli Lilly to $250 From $205, ..
MT
06/14ELI LILLY ANDá : Goldman Sachs Adjusts Eli Lilly's Price Target to $270 From $25..
MT
05/10ELI LILLY ANDá : UBS Adjusts Eli Lilly's Price Target to $193 From $170, Modelin..
MT
04/28ELI LILLY ANDá : Mizuho Adjusts Price Target for Eli Lilly and Company to $216 F..
MT
04/28ELI LILLY ANDá : Goldman Sachs Adjusts Price Target for Eli Lilly and Company to..
MT
04/28ELI LILLY ANDá : Barclays Adjusts Price Target on Eli Lilly to $227 From $232, M..
MT
04/28ELI LILLY ANDá : Morgan Stanley Cuts Price Target on Eli Lilly to $207 From $217..
MT
03/15ELI LILLY ANDá : Truist Securities Adjusts Eli Lilly and Co.'s Price Target to $..
MT
02/04ELI LILLY ANDá : Morgan Stanley Adjusts Eli Lilly's Price Target to $217 From $1..
MT
02/01ELI LILLY ANDá : Truist Securities Adjusts Price Target for Eli Lilly to $215 Fr..
MT
02/01ELI LILLY ANDá : Goldman Sachs Adjusts Price Target for Eli Lilly to $256 From $..
MT
02/01ELI LILLY ANDá : Barclays Adjusts Price Target for Eli Lilly to $232 From $190, ..
MT
02/01ELI LILLY ANDá : JP Morgan Adjusts Price Target for Eli Lilly to $240 From $200,..
MT
02/01ELI LILLY ANDá : Mizuho Adjusts Eli Lilly and Co.'s Price Target to $228 From $2..
MT
01/28ELI LILLY ANDá : Berenberg Adjusts Eli Lilly's Price Target to $190 From $150, R..
MT
01/22ELI LILLY ANDá : BofA Securities Adjusts Eli Lilly and Company PT to $225 From $..
MT
01/19ELI LILLY ANDá : Mizuho Upgrades Eli Lilly and Co. to Buy from Neutral, Adjusts ..
MT
2020ELI LILLY ANDá : UBS Adjusts Price Target on Eli Lilly and Co. to $170 From $166..
MT
2020AbCellera Biologics shares more than triple in stellar debut
RE
2020ELI LILLY ANDá : Wolfe Research Upgrades Eli Lilly and Company to Outperform Fro..
MT
2020ELI LILLY ANDá : Berenberg Adjusts Price Target on Eli Lilly to $150 From $144, ..
MT
2020ELI LILLY ANDá : Mizuho Securities Adjusts Eli Lilly and Company PT to $156 From..
MT
2020ELI LILLY ANDá : Bernstein Reinstates Eli Lilly at Market Perform with $150 Pric..
MT
2020SHANGHAI JUNSHI BIOSCIENCESá : May Benefit From Covid-19 Neutralising Antibody
DJ
2020Hospitalized Covid-19 Patients Recovered Faster With Arthritis Drug
DJ
2020SPECIAL REPORT : Big Pharma wages stealth war on drug price watchdog
RE
2019Teva's new migraine drug helps to contain profit fall
RE
2018Trulicity leads mixed third quarter for Lilly; shares sink
RE
2018Galapagos, Gilead bask in $4-6 billion new drug sales hope
RE
2018Upbeat Roche bests rival Novartis as new drugs fuel growth
RE
2016Drugmakers under fire for possible U.S. price fixing
RE
2016Drugmaker Sanofi hungry for deals after earnings beat
RE
2016Merck gives cautious 2016 outlook as sales of top medicines lag
RE
2015ELI LILLYá : Lilly beats forecasts on cost cuts, raises 2015 view
RE
2014Novartis sales miss forecast as readies overhaul
RE
2014Trade group seeks more U.S. pressure on India over patent protection
RE
2014Lilly forecasts 2014 profit in line with estimates
RE
2013Bribery scandal dents Big Pharma sales in China, GSK hardest hit
RE
2013Analysis - Bribery scandal dents Big Pharma sales in China, GSK hardest hit
RE
2013Top insulin maker Novo caught up in China's widening drug probes
RE
2013Top insulin maker Novo caught up in China's widening drug probes
RE
2013ELI LILLY & CO.á : Lilly beats forecast, helped by soon-fading Cymbalta
RE
2013Pfizer, Lilly beat Street; generics take toll
RE
2013ELI LILLY & CO.á : Lilly says generic competition hurts fourth-quarter profit, s..
RE
2013EXCLUSIVE : Disney looks for cost savings, ponders layoffs - sources
RE
2013"Cliff" concerns give way to earnings focus
RE
2013Alimta patent seen as Lilly's "wild card"
RE
2012J&J hit by strong dollar, CEO eyes pruning units
RE
2012Pfizer plans animal health IPO
RE
2012ELI LILLY & CO.á : Lilly quarterly sales, profit beats forecasts
RE
Official Publications
Upcoming event on ELI LILLY AND COMPANY